Last edition
News about "Hengrui Pharma "
Bristol Myers Squibb and Hengrui Pharma collaborated to jointly develop 13 early-stage programmes across oncology, haematology and immunology, with a potential deal value of up to USD 15.2 billion.
Hengrui Pharma | 13/05/2026 | By News Bureau
Hengrui Pharma and Braveheart Bio have reported positive Phase 2 clinical trial results for investigational cardiac therapy HRS/BHB-1893 in patients with non-obstructive hypertrophic cardiomyopathy, demonstrating improvements in cardiac function, biomarkers and patient outcomes.
Hengrui Pharma | 12/05/2026 | By News Bureau
Hengrui Pharma Grants Braveheart Bio Exclusive Global Rights to Cardiac Myosin Inhibitor HRS-1893
Hengrui Pharma has signed an exclusive licensing deal with US-based Braveheart Bio for its Phase 3-ready cardiac myosin inhibitor HRS-1893. Braveheart will make an upfront payment of USD 65 million and a near-term payment of up to USD 10 million upon technology transfer completion, totalling USD 75 million.
Hengrui Pharma | 06/09/2025 | By Mrinmoy Dey | 557
Hengrui Pharma has signed agreements with GSK to develop up to 12 innovative medicines across respiratory, immunology and inflammation, and oncology. It includes license for potential best-in-class PDE3/4 inhibitor (HRS-9821) in clinical development for treatment of COPD and additional 11 programmes to be developed by Hengrui Pharma and optioned by GSK.
Hengrui Pharma | 28/07/2025 | By Mrinmoy Dey | 332
Merck Signs Exclusive License Deal for HRS-5346 with Hengrui Pharma
Under the agreement, Hengrui Pharma has granted Merck exclusive rights to develop, manufacture and commercialize HRS-5346 worldwide, excluding Greater China region.
Hengrui Pharma | 26/03/2025 | By Aishwarya | 423
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy